Xcout Intel
WallStreetX ETFs, Inc.
Walking Fish Therapeutics develops cell-based therapeutics by engineering B cells to act as protein factories for the treatment of serious diseases, including oncology, regenerative medicine, autoimmune diseases, and rare deficiency diseases. The company utilizes a proprietary B cell platform to deliver various therapeutic proteins such as replacement proteins, immune-inhibitory proteins, and engineered antibodies.
Subscribe to see WallStreetX ETFs, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
WallStreetX ETFs, Inc. at a glance
WallStreetX ETFs, Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $6M in August 2025. Xcout tracks 3 named people at WallStreetX ETFs, Inc., including JOHNNY WU (ISSUER'S CHIEF EXECUTIVE OFFICER).
WallStreetX ETFs, Inc. leadership
- JOHNNY WUISSUER'S CHIEF EXECUTIVE OFFICER
- Lewis “Rusty” WilliamsCo-founder and CEO
- JOHNNY WUExecutive Officer
WallStreetX ETFs, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $6M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
WallStreetX ETFs, Inc. competitors
A few of WallStreetX ETFs, Inc.'s closest competitors — see the full list of competitors and alternatives →
Walking Fish Therapeutics, Inc. is a biotechnology company headquartered in South San Francisco, California, focused on engineering B cell-based protein factories to develop novel biotherapeutics for treating serious diseases.
Blue Marlin Therapeutics is developing a non-viral, in vivo immune-cell engineering platform that combines targeted lipid nanoparticle delivery, genomic integration, and promoter-gated expression. The company aims to provide durable, cell-specific therapies for patients with oncology and autoimmune diseases.
Be Biopharma is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing engineered B cell therapies.
Bellicum Pharmaceuticals, Inc. is a company focused on engineering high-performance cellular immunotherapies. These therapies are developed to combat diseases.
BlueWhale Bio, Inc. is dedicated to accelerating the growth and adoption of cell-based therapies by pioneering next-generation cell therapy manufacturing.
Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.
Get WallStreetX ETFs, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on WallStreetX ETFs, Inc. in Xcout Intel
- 3 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access